Study identifier:D8450R00004
ClinicalTrials.gov identifier:NCT06355934
EudraCT identifier:N/A
CTIS identifier:N/A
OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients with ATTR amyloidosis
ATTR amyloidosis
Phase 4
No
-
All
55000
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
ATTR cardiomyopathy Patients with Transthyretin Amyloidosis Cardiomyopathy | Other: no intervention not applicable, this is an observational retrospective data analysis study; no interventions in the study |
ATTR polyneuropathy Patients with Transthyretin Amyloidosis Neuropathy | Other: no intervention not applicable, this is an observational retrospective data analysis study; no interventions in the study |
ATTR unknown Patients with ATTR unknown genotype | Other: no intervention not applicable, this is an observational retrospective data analysis study; no interventions in the study |
ATTR with mixed phenotype Patients with ATTR mixed phenotype | Other: no intervention not applicable, this is an observational retrospective data analysis study; no interventions in the study |
ATTR wild type Patients with Transthyretin Amyloidosis wild type | Other: no intervention not applicable, this is an observational retrospective data analysis study; no interventions in the study |
ATTR hereditary Patients with Transthyretin Hereditary | Other: no intervention not applicable, this is an observational retrospective data analysis study; no interventions in the study |